Press release
Interview released with Reckitt Benckiser, speaker at Pain Therapeutics 2019
pain, pain therapeutics, analgesic, headache therapy, migraine therapy,
SMi Group are delighted to host the exclusive conference on Pain Therapeutics on the 13th and 14th May 2019 in London, which will bring in expert voices from those at the forefront of technological innovation and analgesic therapies. The 2019 agenda features 15 insightful presentations from the industry leaders.
SMi's interview was with Dalma Sugár, Global Medical Affairs Director, Reckitt Benckiser.
Dalma is a senior medical leader with over 18 years of experience spanning pharmaceutical and consumer health industry, Rx and OTC, having a breadth and depth of experience with medical/clinical and regulatory/safety functions, from both strategic global and local perspective. She has built a career in a variety of roles, started in the governmental sector, then continued in Sanofi Group for 7 years also heading a clinical trial platform later as Regulatory Medical Head for the Sanofi Group leading a portfolio of oncology, cardiovascular, neuroscience, diabetes etc.
In 2012, Dalma joined Reckitt Benckiser as Regional Medical & Regulatory Affairs Head and from beginning of 2016 appointed as Global Medical Affairs Director at the Category Development organization.
The following are excerpts from Dalma's exclusive speaker interview with SMi
Q: The Pain Therapeutics market has matured greatly over recent years, what key differences have you noticed in the last year regarding significant developments?
A: "In the past decades there is an increasing incidence in chronic diseases such as nerve damage, joint pain, back pain, injuries, depression which coupled with increasing geriatric population and changing lifestyle are key factors in driving growth of the pain management therapeutics market. However, side effects caused by certain pain management therapeutics, availability of other generic pain management medications and increasing preference for them, are key factors restraining the growth of the global pain management therapeutics market."
Q: Where do you see the greatest opportunities for analgesic therapeutics leaders in 2019?
"Chronic pain is a major healthcare issue owing to its high prevalence, accompanied by significant physical and emotional burden on the patient and a significant financial burden on the society. It is the leading cause of years lost to disability. There is a huge unmet need for effective medications and innovative alternative solutions in this space, whether it be targeting the chronic pain sufferer itself or the better management of acute pain sufferer and therefore prevention of the chronification of their pain."
Q: Who are you most looking forward to hearing from at the main-conference and why?
A: "I am most looking forward to hearing from Donald Manning on his topic on Therapy for the disease of pain rather than nociceptive masking. I am very interested in learning more about his views on targeting the pathologic response to trauma or injury rather than protective nociception."
You can download the full speaker interview at http://www.pain-therapeutics.co.uk/PR3 just visit the website, download centre.
The two-day conference will showcase a dedicated focus on relevant issues; recent developments in Pain Therapeutics; in-depth case studies including elagolix for treatment of endometriosis pain; spotlight sessions on migraine therapy and 5-HT1F agonist lasmiditan by Eli Lily; a deep dive session on exploring new approaches and struggles to develop pain products; and more.
For those interested in attending, there is a £200 Early Bird discount on bookings expiring on Friday 29th March 2019. Places can be booked at http://www.pain-therapeutics.co.uk/PR3
Pain Therapeutics 2019 is proudly sponsored by CHDR, Lotus Clinical Research, MD Biosciences.
We have tailored sponsorship packages available, if you are interested contact Alia Malick, Director, on +44 (0) 20 827 6168 or email amalick@smi-online.co.uk
For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6000 or ssapal@smi-online.co.uk
Pain Therapeutics 2019
13 – 14 May
Copthorne Tara Hotel, London, UK
Follow us @SMiPharm
#SMiPainTherapeutics
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Marketing Dept, 1st Floor
45 Curlew Street, London, SE1 2ND
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Interview released with Reckitt Benckiser, speaker at Pain Therapeutics 2019 here
News-ID: 1637204 • Views: …
More Releases from SMi Group
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference
The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation.
Industry leaders will uncover the…
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK.
With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading…
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022.
With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and…
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week.
With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman.
The…
More Releases for Pain
Global Pain Management Devices Market Study Analysis: Adoption Of Pain Managemen …
The fast-food market size was valued at $ billion in 2020 and is estimated to reach $ billion by 2028, growing at a CAGR of 6.3% during the forecast period. Pain is an unpleasant sensation and emotional experience caused due to actual or potential tissue damage or illness. Pain can be caused due to accidental injuries, or due to diseases like osteoarthritis, chronic arthritis, diabetic neuropathy, multiple sclerosis, stomach ulcer,…
Flexotone Joint Pain Relief Reviews: Get Relief from Joint Pain & Arthritis
Joint pain & inflammation has come to be an instead usual problem among older consumers, as well as they are frequently entrusted to identify exactly how to deal with these problems with a topical cream or resting. Nevertheless, the makers behind Flexotone think that the reason behind this concern has every little thing to do with something that takes place within the joints. This trouble triggers unbelievable pain; however Big…
Nerve Pain Treatment: 3 Top Neuropathy Pain Relief Pills
Neuropathy affects your extremities or nerves by producing tingling, discomfort, or numbness. Diabetics frequently suffer from neuropathy. According to the American Diabetes Association, around 65 percent of people suffering from diabetes face varying degrees of nerve damage, which results in diabetic neuropathy.
Neuropathy can also occur due to different reasons, like alcoholism, trauma, or autoimmune disorders. Some people acquire neuropathy due to physical injury to their nerves, for instance. Others have…
Post-operative Pain Management Market 2018 by Pain Type - Acute Pain, Moderate P …
Post-operative Pain Management Market 2018 Research Report implements an exhaustive study on Market Research Future. This Report Cover Key Market Driver, market size, growth rate, opportunities, market Dynamics and Overall Analysis. And also cover the other information such as Post-operative Pain Management Market trends, Prominent players, chapter-wise Description followed by various user perceptions and Forecast till 2023.
Global Post-operative Pain Management Market - Overview
Post-operative pain management is the most important part…
Opioids – Reducing body pain but increasing pain for regulatory authorities
Opioids are drugs primarily prescribed for pain management and treatment of diarrhea and cough. Opioid drugs are of two types namely, agonist and antagonist. Codeine, Fentanyl, Meperidine, Methadone, Morphine, Hydrocodone, Diphenoxylate, Hydromorphone, Methylphenidate, Oxycodone, and Oxymorphone are classified as agonists, while Buprenorphine, Naloxone, Naltrexone, Methylnaltrexone, and Nalbuphine are classified as antagonists. Due to easy availability of opioids, these drugs are rampantly overused globally and the situation is more critical in…
Middle East Tapentadol Market by Therapeutic Application Pain Management Neuropa …
Tapentadol is an opioid analgesic, indicated for severe pain management, on a daily or around the clock need for treatment and long-term opioid treatment, for which alternative treatment options are inadequate. Tapentadol is also indicated for neuropathic pain associated with diabetic peripheral neuropathy. It is widely used for management of acute, chronic, and cancer related pain among patients and is available legally on prescription. Nucynta ER is the first and…
